Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589075 | 0.88 | CA9 (0.37) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL3603227 | 0.82 | CREBBP (0.32) | CREBBP | |
| SCHEMBL13545277 | 0.78 | ALDH1A1 (0.34) | MAPTMEN1KMT2ACRBNCREBBP | |
| SCHEMBL16399613 | 0.78 | CREBBP (0.47) | MAPTGAACREBBP | |
| SCHEMBL3996625 | 0.77 | PNMT (0.50) | MEN1GAAKMT2ATDP2PNMT | |
| SCHEMBL3218057 | 0.76 | CA9 (0.51) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL1709931 | 0.76 | CA9 (0.51) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL7826445 | 0.74 | CA9 (0.43) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL3602382 | 0.74 | TRPV1 (0.45) | CA9MAPTKDM4EMEN1GAA | |
| SCHEMBL3601734 | 0.73 | CA9 (0.37) | CA9MAPTKDM4EMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| CN-101589038-A | Heterocyclidene-N-(aryl)acetamide derivative | MOCHIDA PHARM CO LTD (JP) | 2009-11-25 | — | — | CN | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CA9 1812/4885MAPT 755/4885KDM4E 4114/4885 |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CA9 1812/4885MAPT 755/4885KDM4E 4114/4885 |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CA9 1908/4885MAPT 716/4885KDM4E 4218/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CA9 1823/4885MAPT 653/4885KDM4E 4024/4885 |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | CA9 1531/4885MAPT 4758/4885KDM4E 2284/4885 |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CA9 1812/4885MAPT 755/4885KDM4E 4114/4885 |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | CA9 1812/4885MAPT 755/4885KDM4E 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.